Report
Pierre François Merveille

Teva : Recommandation Achat sur les nouvelles obligations SLN 2031

Underlying
Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries is engaged in the development, manufacturing, marketing and distribution of generic, specialty, and other pharmaceutical products. The Generic Medicines segment offers a range of basic chemical entities, as well as specialized product families such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. Co.'s specialty medicines business is focused on delivering innovative solutions to patients and providers via medicines, devices and services, includes Co.'s core therapeutic areas of the central nervous system and respiratory medicines.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Pierre François Merveille

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch